FDA Flags CAPA Gaps in Warning Letter to Intas Pharmaceuticals

The U.S. Food and Drug Administration has issued a warning letter to Intas Pharmaceuticals Limited, highlighting critical shortcomings in its corrective and preventive action (CAPA) processes and quality oversight systems.

The regulator pointed to repeated failures in investigating out-of-specification (OOS) results, noting that existing CAPAs were not robust enough to prevent recurring stability issues. The company’s explanation attributing failures to “product behavior” was deemed scientifically inadequate, particularly when changes in analytical methods produced differing results. The FDA stressed the need for deeper investigations into method variability and validation gaps.

Concerns were also raised over inadequate documentation, including instances where OOS results were invalidated without sufficient evidence and without implementing corrective actions such as analyst training or broader batch reviews.

Additionally, the FDA criticised lapses in data integrity, citing unauthorized edits to electronic batch records that were not captured in audit trails or managed within the quality system. The agency emphasised that all such changes must be properly documented, investigated, and supported by effective CAPA measures and oversight.

04-05-2026